Document is current
Any future updates will be listed below
-
Authors
Stiff, Andrew
Fornerod, Maarten https://orcid.org/0000-0002-6166-3030
Kain, Bailee N. https://orcid.org/0000-0002-8407-9937
Nicolet, Deedra https://orcid.org/0000-0001-7796-0251
Kelly, Benjamin J. https://orcid.org/0000-0002-7796-3994
Miller, Katherine E.
Mrózek, Krzysztof https://orcid.org/0000-0002-1408-5063
Boateng, Isaiah
Bollas, Audrey
Garfinkle, Elizabeth A. R.
Momoh, Omolegho https://orcid.org/0000-0003-3210-5272
Fasola, Foluke A.
Olawumi, Hannah O.
Mencia-Trinchant, Nuria
Kloppers, Jean F. https://orcid.org/0000-0002-8148-1242
van Marle, Anne-Cecilia https://orcid.org/0000-0002-6569-4061
Hu, Eileen
Wijeratne, Saranga
Wheeler, Gregory https://orcid.org/0000-0002-3291-6537
Walker, Christopher J.
Buss, Jill
Heyrosa, Adrienne
Desai, Helee
Laganson, Andrea
Hamp, Ethan
Abu-Shihab, Yazan
Abaza, Hasan
Kronen, Parker
Sen, Sidharth
Johnstone, Megan E.
Quinn, Kate https://orcid.org/0009-0004-2766-3303
Wronowski, Ben
Hertlein, Erin
Miles, Linde A. https://orcid.org/0000-0003-3578-2842
Mims, Alice S. https://orcid.org/0000-0002-8971-2199
Oakes, Christopher C. https://orcid.org/0000-0001-8000-9694
Blachly, James S. https://orcid.org/0000-0002-4275-5562
Larkin, Karilyn T. https://orcid.org/0000-0002-1898-9836
Mundy-Bosse, Bethany
Carroll, Andrew J. https://orcid.org/0000-0001-9844-730X
Powell, Bayard L.
Kolitz, Jonathan E.
Stone, Richard M. https://orcid.org/0000-0002-7526-2633
Duarte, Cassandra
Abbott, Diana
Amaya, Maria L.
Jordan, Craig T. https://orcid.org/0000-0003-0869-3465
Uy, Geoffrey L.
Stock, Wendy
Archer, Kellie J. https://orcid.org/0000-0003-1555-5781
Paskett, Electra D.
Guzman, Monica L.
Levine, Ross L. https://orcid.org/0000-0002-7884-1905
Menghrajani, Kamal
Chakravarty, Debyani https://orcid.org/0000-0001-8629-5732
Berger, Michael F. https://orcid.org/0000-0003-3882-5000
Bottomly, Daniel
McWeeney, Shannon K. https://orcid.org/0000-0001-8333-6607
Tyner, Jeffrey W. https://orcid.org/0000-0002-2133-0960
Byrd, John C.
Salomonis, Nathan https://orcid.org/0000-0001-9689-2469
Grimes, H. Leighton https://orcid.org/0000-0001-8162-6758
Mardis, Elaine R. https://orcid.org/0000-0002-5892-1553
Eisfeld, Ann-Kathrin https://orcid.org/0000-0001-6442-1419
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA262496, R01 CA284595-01, R01 CA283574-01, R01 LM013879, R01 CA262496)
Conquer Cancer Foundation (2023YIA-5335030875)
- License Information
-
More Information
Article History
Received: 20 December 2023
Accepted: 23 August 2024
First Online: 4 October 2024
Competing interests
: C.J.W. is a consultant for Vigeo Therapeutics and is employed by Karyopharm Therapeutics; he has ownership interest in Karyopharm Therapeutics and Bristol Myers Squibb Co. A.S.M. has served in a consulting or advisory role for AbbVie, Bristol Meyers Squibb, Novartis and Treadwell Therapeutics; he has served on a data monitoring safety committee for Daiichi Sankyo and Foghorn Therapeutics and currently serves as a Senior Medical Director for the Leukemia and Lymphoma Society Beat AML Study. J.S.B. is a consultant and advisory board member for AbbVie, AstraZeneca, Syndax, INNATE and KITE. B.L.P. has received honoraria from Jazz Pharmaceuticals, Novartis and Pfizer. J.F.K. has received honoraria from Gilead, Magellan and Novartis; consulting fees from Gilead, Magellan, Novartis, Pharmacyclics and Seattle Genetics; institutional research funding from Boehringer Ingelheim, Cantex, Erytech and Millennium; and travel support from Gilead, Novartis and Seattle Genetics. R.M.S. has served on independent data safety monitoring committees for trials supported by Celgene, Takeda and Argenx; has consulted for AbbVie, Actinium, Agios, Amgen, Arog, Astellas, AstraZeneca, BioLineRx, Celgene, Daiichi Sankyo, Fujifilm, Janssen, Juno, Macrogenics, Novartis, Ono, Orsenix, Pfizer, Roche, Stemline Therapeutics, Sumitomo, Takeda and Trovagene; and has received research support (to his institution) for clinical trials sponsored by AbbVie, Agios, Arog and Novartis. E.D.P. has received grants from the Merck Foundation and Pfizer. M.L.G. holds research contracts and consults with Bridge Medicines and holds stock options for SeqRx. M.F.B. has a consultancy role with AstraZeneca, Eli Lilly and Paige.AI and has received research support from Boundless Bio. J.C.B. has a consultancy and advisory role with Syndax, Novartis and Vincera; research funding from Pharmacyclics, an AbbVie company, Genentech, Janssen and Acerta; and ownership for Vincera. E.R.M. has received research support (to her institution) from Pfizer, the Merck Foundation, Genentech, Guardant Health and Astra Zeneca; and has served as an advisory board member for GSK and Merck, and as member of the Board of Directors of the Alliance Foundation and American Association for Cancer Research. R.L.L. is on the supervisory board of QIAGEN and is a scientific adviser to Imago, Mission Bio, Syndax, Zentalis Pharmaceuticals, Ajax, Bakx, Auron, Prelude, C4 Therapeutics and Isoplexis, for which he receives equity support. R.L.L. receives research support from Ajax and Abbvie and has consulted for Incyte, Janssen, MorphoSys and Novartis. He has received honoraria from AstraZeneca and Incyte for invited lectures. A.-K.E. has received a research grant from Novartis, and an honorarium from AstraZeneca for serving on their Diversity, Equity and Inclusion Advisory Board; her spouse has ownership interest in Karyopharm Therapeutics. The other authors declare no completing interests.
